tiprankstipranks
Trending News
More News >

Teva initiated with a Buy at Truist

Truist initiated coverage of Teva (TEVA) with a Buy rating and $25 price target Teva’s dual focus on cultivating its high-margin brands while strengthening generics continues to de-risk the topline and margin profile, says the analyst, who sees management executing well against the company’s “Pivot to Growth” plan. The firm sees potential line of sight to 30% operating margin by 2027, the analyst added.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1